Advisory Services Network LLC Has $5.35 Million Stock Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Advisory Services Network LLC increased its position in Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) by 0.9% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,462 shares of the company’s stock after purchasing an additional 152 shares during the quarter. Advisory Services Network LLC’s holdings in Medpace were worth $5,353,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in MEDP. RiverPark Advisors LLC bought a new position in shares of Medpace in the fourth quarter valued at $26,000. Contravisory Investment Management Inc. bought a new position in Medpace in the 4th quarter valued at about $26,000. GAMMA Investing LLC acquired a new position in Medpace during the 4th quarter valued at about $30,000. McGlone Suttner Wealth Management Inc. bought a new stake in Medpace during the 4th quarter worth approximately $33,000. Finally, Principal Securities Inc. purchased a new stake in shares of Medpace in the fourth quarter worth approximately $68,000. 77.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on MEDP. StockNews.com raised Medpace from a “hold” rating to a “buy” rating in a research report on Tuesday, April 23rd. Guggenheim lifted their price objective on shares of Medpace from $453.00 to $464.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Deutsche Bank Aktiengesellschaft started coverage on shares of Medpace in a report on Monday, March 18th. They issued a “hold” rating and a $395.00 target price for the company. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and boosted their price target for the stock from $340.00 to $450.00 in a report on Tuesday, April 23rd. Finally, Robert W. Baird increased their price objective on shares of Medpace from $446.00 to $454.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Medpace currently has a consensus rating of “Moderate Buy” and an average price target of $443.00.

View Our Latest Stock Analysis on MEDP

Insider Buying and Selling

In other news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the transaction, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO August J. Troendle sold 25,000 shares of Medpace stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $408.71, for a total value of $10,217,750.00. Following the transaction, the chief executive officer now owns 4,733,019 shares in the company, valued at $1,934,432,195.49. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Susan E. Burwig sold 102 shares of the stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the sale, the vice president now owns 15,181 shares of the company’s stock, valued at $6,117,943. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 145,291 shares of company stock worth $59,648,117. Corporate insiders own 20.30% of the company’s stock.

Medpace Trading Down 0.0 %

Shares of NASDAQ:MEDP traded down $0.03 during mid-day trading on Friday, reaching $390.55. The company had a trading volume of 112,402 shares, compared to its average volume of 190,675. The company’s 50-day moving average price is $395.33 and its 200-day moving average price is $346.12. Medpace Holdings, Inc. has a one year low of $199.20 and a one year high of $421.00. The firm has a market cap of $12.10 billion, a price-to-earnings ratio of 39.81, a PEG ratio of 1.93 and a beta of 1.40.

Medpace (NASDAQ:MEDPGet Free Report) last issued its earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.75. The firm had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. Medpace had a return on equity of 59.74% and a net margin of 15.92%. The business’s revenue was up 17.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.27 earnings per share. On average, research analysts anticipate that Medpace Holdings, Inc. will post 11.29 EPS for the current fiscal year.

Medpace Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Featured Articles

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.